Is CJC-1295 DAC legal to buy in the United States for research? Researchers sourcing GHRH analogs for growth hormone axis studies run into this question regularly, often alongside questions about the difference between DAC and no-DAC variants. The legal answer is clear: CJC-1295 DAC is not a controlled substance under the Controlled Substances Act, has no FDA approval for human use, and is commercially available for laboratory research in the US.
CJC-1295 DAC Regulatory Status in the United States
CJC-1295 DAC is a modified growth hormone-releasing hormone (GHRH) analog. The DAC designation refers to Drug Affinity Complex technology — a maleimide-derivatized lysine residue appended to the C-terminus that allows the peptide to reversibly bind serum albumin. This modification extends plasma half-life from roughly 30 minutes (for CJC-1295 without DAC) to approximately six to eight days in published pharmacokinetic studies.
Neither form appears on the DEA’s Schedule I–V list of controlled substances (21 CFR Part 1308), and neither has been placed under Emergency Scheduling. The FDA has not approved CJC-1295 DAC as a drug product for human therapeutic use. That positions it in the same regulatory space as many research peptides: not prohibited, not approved for clinical use, and legally available for legitimate scientific research.
The DAC modification itself — the chemical addition that changes the pharmacokinetics — does not alter the compound’s regulatory classification. Researchers sometimes assume that a structurally modified analog might have different legal status than its parent compound; in this case, it does not.
The Pharmacokinetic Difference That Drives Research Decisions
Understanding why researchers specifically order the DAC form rather than CJC-1295 No DAC is important context for sourcing decisions. CJC-1295 No DAC produces a short burst of GHRH receptor stimulation aligned with natural GH pulse timing. The DAC variant produces sustained GHRH receptor occupancy over multiple days from a single administration.
Published studies comparing the two forms have examined tonic versus pulsatile GH secretion profiles and their downstream effects on IGF-1 levels and body composition markers in rodent models. These are distinct research questions that require distinct compounds — using the wrong form, or receiving a mislabeled product, would produce data inconsistent with any published reference that used the correctly specified variant.
This is one reason third-party mass spectrometry data matters beyond basic purity confirmation. The molecular weight of CJC-1295 DAC is substantially higher than the no-DAC form due to the albumin-binding linker — verifying the MS result against the expected MW for the DAC form is the only way to confirm the modification is actually present, not just assumed from labeling.
Research-Use Compliance for CJC-1295 DAC
The legal framework for purchasing CJC-1295 DAC for research is the same framework that applies to unscheduled, unapproved compounds generally. The compound must be acquired for legitimate laboratory research use — not personal administration, not for resale as a supplement, not for compounding outside a licensed facility. The supplier must represent the product accurately without therapeutic or human-use claims. The research environment should involve appropriate documentation, protocols, and accountability.
Blank Peptides produces CJC-1295 DAC in cGMP labs in the USA. Each lot is independently tested by Freedom Diagnostics and Horizon Analytical, with results showing >99% purity by HPLC and molecular identity confirmed by mass spectrometry. Processing time for orders is within 1 business day.
For GH axis protocols, ipamorelin is commonly ordered alongside CJC-1295 DAC. The two peptides act on complementary receptor systems — ipamorelin on GHS-R1a, CJC-1295 DAC on the GHRH receptor — and published studies have examined their combined use in sustained GH secretion protocols. Both are unscheduled in the US and available under the same research-use framework.
Important Distinctions for Researchers
A few points that come up regularly when researchers are working through compliance questions for the first time:
The research-use exemption is not ambiguous legal cover — it is an accurate description of the commercial channel. Unscheduled, unapproved compounds are sold legally for research because US law permits it for legitimate scientific purposes. Mischaracterizing a personal-use purchase as research is where legal exposure arises, not in legitimate laboratory use.
Anti-doping rules are a separate framework. WADA classifies GHRH analogs under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which means CJC-1295 DAC is prohibited in competitive sport contexts. This is a sports governance rule enforced through athlete testing programs — it has no bearing on legal laboratory research purchasing in the US and should not be confused with DEA or FDA status.
International shipments involve additional considerations. While US research-use purchase is legally clear, some countries schedule or restrict GHRH analogs differently. Researchers at institutions outside the US, or those purchasing for cross-border research programs, should verify local regulatory status before ordering.
FAQ
Does the DAC modification change the legal classification of the compound?
No. The albumin-binding linker added by DAC technology is a synthetic chemical modification that alters pharmacokinetics but does not place the peptide in a different regulatory category. Both CJC-1295 DAC and CJC-1295 No DAC are unscheduled under the CSA, and neither has FDA approval. Regulatory status is determined by scheduling and approval processes, not by the presence of a chemical modification.
How can I confirm that the CJC-1295 DAC I receive actually contains the DAC modification?
Mass spectrometry is the definitive method. The expected molecular weight of CJC-1295 DAC is significantly higher than CJC-1295 No DAC — the difference reflects the added molecular mass of the maleimide-lysine DAC component. When reviewing a COA, the observed MW from the MS result should match the expected MW for the DAC form. If a supplier’s documentation shows only HPLC area% purity without a MS result, you cannot confirm which form you have received from the paperwork alone.
Is CJC-1295 DAC subject to any prescription requirements in the US?
No. As an unscheduled compound with no FDA approval as a prescription drug, CJC-1295 DAC is not subject to prescription requirements for laboratory research purchasing. Pharmacy channels are a separate matter — compounding of GHRH analogs under 503A and 503B frameworks involves a distinct regulatory process — but purchasing as a research compound for institutional laboratory use does not require a prescription.
All products discussed are for laboratory research use only and are not for human or veterinary use.